Latest News and Press Releases

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has...

Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Octreotide Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides an...

Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global market for somatostatin...

New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...

New York, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is predicted to expand at ~ 6% CAGR between 2023 and 2035. The market is projected to garner a revenue of USD...

SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

Dublin, July 25, 2022 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global...

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the...

- IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors’ appointments - SAN...